Matthew Yeowart
Lawyers
Filters
Roche $7.1 billion acquisition of Telavant and rights to RVT 3101 from Roivant
We are advising Roche on the acquisition
Instant Brands sale of substantially all of its assets to Centre Lane Partners
We are advising Instant Brands on the sale
Orogen Group investment in Brillio
We advised the Orogen Group on the investment
Diebold Nixdorf emerges from chapter 11 and WHOA and obtains chapter 15 recognition
We advised an ad hoc group of secured creditors in connection with Diebold’s restructuring proceedings
Lucid Group $232 million strategic supply agreement with Aston Martin
We are advising Lucid Group on the transaction
Cadeler $597 million combination with Eneti
We are advising Cadeler on the transaction
Forbion European Acquisition combination with enGene
We are advising Forbion European Acquisition on its de-SPAC transaction
GSK exclusive licensing agreement with Scynexis
We advised GSK on the transaction
Natura $2.525 billion sale of Aesop to L’Oréal
We are advising Natura on the transaction
Japan Industrial Partners $15.2 billion acquisition of Toshiba
We are advising Japan Industrial Partners on the acquisition